CPA
EDIT icon

Capital Performance Advisors’s Editas Medicine EDIT Stock Holding History

Capital Performance Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-761
Closed -$2.6K – 898
2024
Q3 		$2.6K Buy
+761
New +$3.31K ﹤0.01% 1434

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's EDIT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 761 shares — an estimated $2.6K sold.

Capital Performance Advisors first reported a position in EDIT in Q3 2024 and held it in 1 quarter. The position peaked at $2.6K in Q3 2024. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 761 Editas Medicine shares in Q4 2024, an estimated $2.6K.
  • Capital Performance Advisors first reported a position in Editas Medicine in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Editas Medicine position peaked at $2.6K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.